Tyra Biosciences’ (TYRA) Outperform Rating Reaffirmed at Wedbush

Tyra Biosciences (NASDAQ:TYRA)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a research report issued to clients and investors on Friday,RTT News reports. They presently have a $30.00 target price on the stock. Wedbush’s price objective points to a potential upside of 207.06% from the company’s previous close. Wedbush also issued estimates for Tyra Biosciences’ FY2029 earnings at ($0.91) EPS.

Several other brokerages also recently issued reports on TYRA. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a report on Tuesday, February 18th. UBS Group started coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $30.83.

Tyra Biosciences Stock Performance

Shares of NASDAQ TYRA opened at $9.77 on Friday. Tyra Biosciences has a 52-week low of $9.49 and a 52-week high of $29.60. The stock has a market cap of $494.39 million, a P/E ratio of -6.07 and a beta of 1.09. The firm has a 50 day moving average price of $12.46 and a 200 day moving average price of $16.33.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.05. Analysts predict that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Insider Transactions at Tyra Biosciences

In other Tyra Biosciences news, Director Nina S. Kjellson sold 3,993 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total value of $65,325.48. Following the sale, the director now owns 3,707,420 shares in the company, valued at approximately $60,653,391.20. The trade was a 0.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 21,998 shares of company stock valued at $344,818 over the last three months. Company insiders own 15.40% of the company’s stock.

Hedge Funds Weigh In On Tyra Biosciences

Several hedge funds have recently made changes to their positions in the business. KLP Kapitalforvaltning AS acquired a new position in Tyra Biosciences during the fourth quarter worth $31,000. US Bancorp DE acquired a new stake in Tyra Biosciences in the 4th quarter valued at $50,000. BNP Paribas Financial Markets bought a new stake in Tyra Biosciences during the 4th quarter worth about $60,000. Aquatic Capital Management LLC acquired a new position in shares of Tyra Biosciences during the 4th quarter worth about $64,000. Finally, Wells Fargo & Company MN grew its holdings in shares of Tyra Biosciences by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock valued at $132,000 after acquiring an additional 3,236 shares in the last quarter. 84.14% of the stock is owned by institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.